Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2025-12-24 @ 7:52 PM
NCT ID:
NCT04993404
Eligibility Criteria:
Inclusion Criteria:
* Able to comprehend and willing to sign an informed consent form. Ability to comply with trial and follow-up procedures.
* Age 18-79 years at the time of signing the ICF, either male or female.
* Male subjects body weight at least 50 kg, and female subjects body weight at least 45 kg. Body mass index (BMI) between 18 and 32 kg/m2 to participate.
* After physical examination, vital signs, laboratory examinations, 12-lead electrocardiogram examination, the investigator determined that it is suitable to participate in this study.
* Subjects are willing to take effective contraceptive measures from screening to 3 months after administration.
Additional Inclusion Criteria for Hepatic Impaired Subjects Only:
* Child-Pugh Clinical Assessment Score consistent with degree of hepatic impairment(Requires no use of albumin within 14 days), And it is dysfunction caused by previous primary liver disease.
* Any examination such as B-ultrasound, CT, MRI, FibroScan or liver biopsy confirms the presence of cirrhosis.
Additional Inclusion Criteria for Healthy Subjects Only:
* Have not taken any medicine within 2 weeks before administration; or have stable medication for at least 4 weeks before administration for the treatment of other comorbid diseases.
Exclusion Criteria:
* Drug-induced liver injury.
* Acute liver damage caused by various reasons.
* Patients with liver failure, or combined with dominant hepatic encephalopathy, liver cancer, etc., which the investigator believes are not suitable for participating in the study.
* Patients with a history of massive bleeding from esophageal varices without band ligation, sclerosing agent and TIPS treatment
* Subjects with suspected allergies to Jaktinib or its excipient.
* History of blood donation of 400 mL or more of blood within 3 months prior to screening.
* Drug dependency, a positive urine drug screen.
* Subjects with any significant clinical and laboratory abnormalities which may affect the safety evaluation.
* Subjects suffering from arrhythmia and requiring treatment, or QTcB \> 480ms at screening.
* Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal infections requiring treatment at screening.
* Subjects with known human immunodeficiency virus (HIV),
* Subjects with epilepsy or patients who have received psychotropic drug or sedatives during screening.
* Subjects who had experienced malignant tumors within the past 5 years (except for adequately treated local basal cell carcinoma of the skin and cervical carcinoma in situ that have been cured).
* Subjects who have participated in another clinical trial of a new drug or medical instrument within 3 months before screening.
* Females who are breastfeeding or pregnant at Screening.
Exclusion Criteria for Healthy Subjects Only:
* Subjects with hepatitis B surface antigen positive or HCV-RNA positive.
* Patients with a history of liver dysfunction, or physical examination and laboratory examination at screening indicate that there is or may have liver dysfunction.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
79 Years
Study:
NCT04993404
Study Brief:
Protocol Section:
NCT04993404